comparemela.com

Page 3 - Bergenbio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BerGenBio ASA: BerGenBio reports second quarter and half year 2022 financial results and provides business update

Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 BerGenBio to host conference call and webcast today

United kingdomUnited statesGraham morrellCristina olivaMipasetamab uzoptirineMartin olinPrnewswire bergenbioUt southwestern medical centerAmerican society of clinical oncologyIqvia ltdClinical developmentOslo stock exchangeHead of oncology centre excellenceChief executive officerNon small cell lung cancerMedical center

BerGenBio ASA: BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer

BERGEN, Norway, April 11, 2022 /PRNewswire/ BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs

United kingdomChris welshCristina olivaMartin olinMary jane elliottEli lillyPrnewswire bergenbioLucy featherstoneInternational media relationsTakeda pharmaceuticalsClinical research organizations crosHead of oncology centre excellenceOslo stock exchangeConsilium strategic communicationsChief medical officerClinical research organizations

BerGenBio ASA: BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021

BERGEN, Norway, April 7, 2022 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs

United kingdomChris welshMartin olinMary jane elliottPrnewswire bergenbioLucy featherstoneInternational financial reporting standardsInternational media relationsConsilium strategic communicationsOslo stock exchangeFinancial statementsAnnual reportJane elliottNorwegian securities trading

BerGenBio ASA: BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients

BERGEN, Norway, Jan. 27, 2022 /PRNewswire/ BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs

United kingdomChris welshMary jane elliottMartin olinEli lillyPrnewswire bergenbioLucy featherstoneEuropean union horizonLinstitut national de la santInternational media relationsEuropean medicines agencyOslo university hospitalOslo stock exchangeConsilium strategic communicationsEuropean clinical research infrastructure networkEmerging infection platform trial

Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting

- Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients BERGEN, Norway, June 11, 2021 /PRNewswire/ BerGenBio ASA (OSE: BGBIO)

United kingdomChris welshCarina jursMary jane elliottRichard godfreyPrnewswire bergenbioLucy featherstoneEuropean haematology associationInternational media relationsConsilium strategic communicationsOslo stock exchangeAcute myeloid leukaemiaSonja logesPrincipal investigatorMyeloid leukaemiaJane elliott

vimarsana © 2020. All Rights Reserved.